Issn: 2036-5438
نویسنده
چکیده
منابع مشابه
Noninvasive coronary angiography using computed tomography: ready to kick it up another notch?
Copyright © 2002 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online 72514 Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX DOI: 10.1161/01.CIR.0000037740.97150.43 2002;106;2036-2038 Circulation John A. Rumberger Kick It Up Another Notch? Noninvasive Coronary Angiography Using Computed Tomography: Ready to http://circ.ahaj...
متن کاملThe Conformational Control Inhibitor of Tyrosine Kinases DCC-2036 Is Effective for Imatinib-Resistant Cells Expressing T674I FIP1L1-PDGFRα
The cells expressing the T674I point mutant of FIP1-like-1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRα) in hypereosinophilics syndrome (HES) are resistant to imatinib and some second-generation tyrosine kinase inhibitors (TKIs). There is a desperate need to develop therapy to combat this acquired drug resistance. DCC-2036 has been synthesized as a third-generation TKI to combat...
متن کاملThe ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABL and Exhibits a Narrow Resistance Profile
Acquired pointmutationswithin the BCR-ABL kinase domain represent a commonmechanismof resistance to ABL inhibitor therapy in patients with chronic myeloid leukemia (CML). The BCR-ABL mutant is highly resistant to imatinib, nilotinib, and dasatinib, and is frequently detected in relapsed patients. This critical gap in resistance coverage drove development of DCC-2036, an ABL inhibitor that binds...
متن کاملThe ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
Acquired point mutations within the BCR-ABL kinase domain represent a common mechanism of resistance to ABL inhibitor therapy in patients with chronic myeloid leukemia (CML). The BCR-ABL(T315I) mutant is highly resistant to imatinib, nilotinib, and dasatinib, and is frequently detected in relapsed patients. This critical gap in resistance coverage drove development of DCC-2036, an ABL inhibitor...
متن کاملFamily Limited Partnerships : Taxes , Courts , and an Uncertain Future — Part I
The family limited partnership (“FLP”) has ascended to the summit of favored estate planning techniques in the past decade or so.1 For years, the FLP appeared to be almost invincible, although the Internal Revenue Service (“Service”) volleyed numerous attacks at the FLP, only to be repeatedly defeated by the courts—that is, until recently. In several recent cases, the Service has successfully f...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2014